{"analyses":[{"ciLowerLimit":"1.12","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.31","estimateComment":"Based on a cLDA model with the PRO scores as the response variable with covariates for treatment by time interaction, stratification factors (IMDC Risk Category, and Number of Prior VEGF/VEGF-Receptor Targeted Therapies for RCC) as covariates.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0051","paramType":"Difference in LS Means","paramValue":"3.72","statisticalMethod":"t-test, 2 sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.03","upperLimit":"1.65","value":"-0.19"},{"groupId":"OG001","lowerLimit":"-5.86","upperLimit":"-1.96","value":"-3.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"363"},{"groupId":"OG001","value":"353"}],"units":"Participants"}],"description":"The EQ-5D-5L questionnaire assesses 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/ depression. Each dimension has 5 response options that reflect increasing levels of difficulty, which are coded on a scale from 1 (no problems) to 5 (extreme problems). The VAS is a component of EQ-5D-5L that asks participants to rate their overall health on a vertical visual analogue scale, with the scale's ends labelled 'The best health you can imagine' (equivalent to a score of 0) and 'The worst health you can imagine' (equivalent to a score of 100). The change from baseline to Week 17 in Health Utility using the EQ-5D-5L VAS score was calculated based on a constrained longitudinal data analysis (cLDA) model with the PRO scores as response variable with covariates for treatment by time interaction, stratification factors (IMDC Risk Category, and Number of Prior VEGF/VEGF-Receptor Targeted Therapies for RCC) as covariates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Randomized participants received 120 mg of belzutifan orally once daily (QD), until disease progression or discontinuation.","id":"OG000","title":"Belzutifan"},{"description":"Randomized participants received 10 mg of Everolimus orally QD, until disease progression or discontinuation.","id":"OG001","title":"Everolimus"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Per protocol, the analysis population consisted of all randomized participants who have received at least one dose of the study intervention with assessments available for EQ-5D-5L at baseline or post-baseline up to Week 17; and had data available in this change from baseline in VAS Score using EQ-5D-5L. Per protocol, participants enrolled in the Safety Run-In were not randomized and not included in the protocol-specified analyses for any of the outcome measures.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1) and week 17","title":"Change From Baseline to Week 17 in Visual Analogue Scale (VAS) Score on the European Quality of Life 5 Dimension, 5-level Questionnaire (EQ-5D-5L) Health Utility Score","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}